title: Efficient mobilization of PBSC with vinorelbine/G-CSF in patients with malignant lymphoma.
abstract: High-dose chemotherapy (HDT) and hematopoietic SCT are effective in patients with relapsing or refractory malignant lymphoma. Collection of sufficient numbers of stem cells is a prerequisite for such a therapy. In a pilot trial, we evaluated the feasibility of stem cell mobilization with vinorelbine/G-CSF in patients with lymphoma, a regimen allowing precise timing and harvesting of sufficient stem cells in myeloma patients. Forty-five patients with lymphoma received vinorelbine 35 mg/m(2) i.v. on day 1 and G-CSF 10 microg/kg/day s.c., divided in two daily doses from day 4 until collection. Stem cell collection was successfully performed in 43 patients (96%) with a median of 3.6 x 10(6) CD34(+) cells/kg (range: 1.4-16) in the collected product. In 28 patients (62%), the first stem cell apheresis was performed on day 8, and for 28 patients a sufficient stem cell yield was reached with one apheresis only. All 43 patients underwent high-dose chemotherapy with BEAM and auto-SCT with hematological recovery on time and without unexpected toxicity. In conclusion, vinorelbine/G-CSF allows accurate timing and safe harvesting of sufficient stem cells in patients with malignant lymphoma.
authors.affiliation: Center of Oncology/Hematology and Transfusion Medicine, Kantonsspital Aarau, Aarau, Switzerland. marc.heizmann@ksa.ch
authors.forename: M
authors.initials: M
authors.lastname: Heizmann
authors.forename: A C
authors.initials: AC
authors.lastname: O'Meara
authors.forename: P R
authors.initials: PR
authors.lastname: Moosmann
authors.forename: I A F M
authors.initials: IA
authors.lastname: Heijnen
authors.forename: M
authors.initials: M
authors.lastname: Zuberbühler
authors.forename: P
authors.initials: P
authors.lastname: Fernandez
authors.forename: J
authors.initials: J
authors.lastname: Burger
authors.forename: A
authors.initials: A
authors.lastname: Huber
authors.forename: M
authors.initials: M
authors.lastname: Wernli
authors.forename: M J
authors.initials: MJ
authors.lastname: Bargetzi
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D016527:Drug Costs; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage / Q000627:therapeutic use*; D019650:Hematopoietic Stem Cell Mobilization / Q000379:methods*; D018380:Hematopoietic Stem Cell Transplantation; D006689:Hodgkin Disease / Q000628:therapy*; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000628:therapy*; D008875:Middle Aged; D010865:Pilot Projects; D014182:Transplantation, Autologous; D014747:Vinblastine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000077235:Vinorelbine
chemical_list: D016179:Granulocyte Colony-Stimulating Factor; D014747:Vinblastine; D000077235:Vinorelbine